Show simple item record

dc.contributor.authorZhao, Sizheng Steven
dc.contributor.authorYoshida, Kazuki
dc.contributor.authorJones, Gareth T.
dc.contributor.authorHughes, David M.
dc.contributor.authorDuffield, Stephen J.
dc.contributor.authorTedeschi, Sara K.
dc.contributor.authorLyu, Houchen
dc.contributor.authorMoots, Robert J.
dc.contributor.authorSolomon, Daniel H.
dc.contributor.authorGoodson, Nicola J.
dc.date.accessioned2019-08-28T13:10:08Z
dc.date.available2019-08-28T13:10:08Z
dc.date.issued2019-07-22
dc.identifier.citationZhao , S S , Yoshida , K , Jones , G T , Hughes , D M , Duffield , S J , Tedeschi , S K , Lyu , H , Moots , R J , Solomon , D H & Goodson , N J 2019 , ' Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis ' , Arthritis Research & Therapy , vol. 21 , no. 1 , 177 . https://doi.org/10.1186/s13075-019-1958-zen
dc.identifier.issn1478-6354
dc.identifier.otherPURE: 147102016
dc.identifier.otherPURE UUID: ae4a5520-dcde-4716-b15e-81e522bf67ee
dc.identifier.otherPubMed: 31331375
dc.identifier.otherPubMedCentral: PMC6647300
dc.identifier.otherWOS: 000476712900001
dc.identifier.otherMendeley: 2c082130-ea08-36a1-a666-a867c4731854
dc.identifier.otherScopus: 85069759314
dc.identifier.otherORCID: /0000-0003-0016-7591/work/83703976
dc.identifier.urihttp://hdl.handle.net/2164/12801
dc.identifier.urihttp://www.mendeley.com/research/smoking-status-causespecific-discontinuation-tumour-necrosis-factor-inhibitors-axial-spondyloarthriten
dc.descriptionAvailability of data and materials BSRBR-AS data are held at the University of Aberdeen. Funding The BSRBR-AS is funded by the British Society for Rheumatology (BSR) who have received funding for this from Pfizer, AbbVie and UCB. These companies receive advance copies of manuscripts for comments. They have no input in determining the topics for analysis or work involved in undertaking it. SZ was supported by awards from the Royal College of Physicians (John Glyn bursary) and Royal Society of Medicine (Kovacs fellowship). KY received financial support for his doctoral study from the Pharmacoepidemiology Program at the Harvard T.H. Chan School of Public Health (partially supported by training grants from Pfizer, Takeda, Bayer and ASISA) and Honjo International Scholarship Foundation. DHS was supported by grants from the National Institute of Health (NIH-P30-AR072577 (VERITY) and NIH-K24AR055989) and has received funding from Abbvie and Amgen unrelated to this work. Acknowledgements We are grateful to Professor Gary Macfarlane (Chief Investigator of BSRBR-AS) and the staff of the BSRBR-AS register who are currently Claudia Zabke, Elizabeth Ferguson-Jones, Maureen Heddle, Nafeesa Nazlee and Barry Morris, and to the recruiting staff at the clinical centres, details of which are available at: https://www.abdn.ac.uk/iahs/research/epidemiology/spondyloarthritisen
dc.format.extent7
dc.language.isoeng
dc.relation.ispartofArthritis Research & Therapyen
dc.rights© The Author(s). 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en
dc.subjectAxial spondyloarthritisen
dc.subjectTNF inhibitoren
dc.subjectBiologic DMARDsen
dc.subjectPersistenceen
dc.subjectEffectivenessen
dc.subjectResponseen
dc.subjectDiscontinuationen
dc.subjectMarginal structural modelen
dc.subjectR Medicine (General)en
dc.subjectSupplementary Dataen
dc.subject.lccR1en
dc.titleSmoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritisen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Other Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Epidemiology Groupen
dc.contributor.institutionUniversity of Aberdeen.Institute of Applied Health Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Clinical Medicineen
dc.contributor.institutionUniversity of Aberdeen.Aberdeen Centre for Arthritis and Musculoskeletal Health (ACAMH)en
dc.description.statusPeer revieweden
dc.description.versionPublisher PDFen
dc.identifier.doihttps://doi.org/10.1186/s13075-019-1958-z
dc.identifier.urlhttp://www.mendeley.com/research/smoking-status-causespecific-discontinuation-tumour-necrosis-factor-inhibitors-axial-spondyloarthriten
dc.identifier.vol21en
dc.identifier.iss1en


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record